VIVXF (Avivagen) ROCE %: 0.00% (As of Jul. 2023)


What is Avivagen ROCE %?

Avivagen VIVXF -99.00% ROCE % is 0.00% as of Jul. 2023.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Avivagen's annualized ROCE % for the quarter that ended in Jul. 2023 was 0.00%.

Avivagen  (OTCPK:VIVXF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Avivagen ROCE % Related Terms

Avivagen ROCE % Historical Data

* Premium members only.

The historical data trend for Avivagen's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avivagen ROCE % Chart

Avivagen Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -281.40 -288.14 -1,720.26 0.00 0.00

Avivagen Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,511.11 0.00 0.00 0.00 0.00

Avivagen ROCE % Calculation

Avivagen's annualized ROCE % for the fiscal year that ended in Oct. 2022 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Oct. 2022 )  (A: Oct. 2021 )(A: Oct. 2022 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Oct. 2022 )  (A: Oct. 2021 )(A: Oct. 2022 )
=-3.14/( ( (2.797 - 4.837) + (0.997 - 1.533) )/ 2 )
=-3.14/( (-2.04+-0.536)/ 2 )
=-3.14/-1.288
=243.79 %

Avivagen's ROCE % of for the quarter that ended in Jul. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jul. 2023 )  (Q: Apr. 2023 )(Q: Jul. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jul. 2023 )  (Q: Apr. 2023 )(Q: Jul. 2023 )
=-1.292/( ( (0.241 - 5.414) + (0.207 - 6.386) )/ 2 )
=-1.292/( ( -5.173 + -6.179 )/ 2 )
=-1.292/-5.676
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Jul. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Avivagen (VIVXF) has a ROCE % of 0.00% as of Jul. 2023.
Is Avivagen's ROCE % too high?
Avivagen's current ROCE % is 0.00%.
How does Avivagen's ROCE % compare to DMKPQ and MJNE?
Avivagen's ROCE % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avivagen's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avivagen stock overvalued right now?
Avivagen (VIVXF) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Avivagen (VIVXF), the current ROCE % is 0.00% as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avivagen Business Description

Address 100 Sussex Drive, Ottawa, ON, CAN, K1A 0R6
Avivagen Inc OxC-beta technology is derived from Avivagen discoveries about Beta-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxCbeta Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. Avivagen's OxC-beta Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters.